The Board of directors of the Zhongzhi Pharmaceutical Holdings Limited announced that based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2020 and the information currently available to the Board, the Group is expected to record a significant increase of approximately over 20% in net profit for the six months ended 30 June 2020 as compared with the corresponding period in 2019. Such expected increase is mainly due to Caojinghua Cell-broken Herb, the main product line of the company, continues to receive growing recognition from the consumers.